Oklo Inc. (OKLO) rose 2.35% to $61.09, recovering after earlier volatility as regulatory progress supported expansion plans. The company secured a key U.S. license and advanced reactor development agreements. These steps strengthen its transition from planning to operational execution in nuclear and isotope markets.
Oklo received its first materials license from the U.S. Nuclear Regulatory Commission through its subsidiary Atomic Alchemy. The approval allows handling, processing, and distribution of key radioactive isotopes. This step moves the company into early-stage commercial isotope operations.
The license permits activities involving limited quantities of radium-226 and sealed calibration sources. It also supports chemical processing, storage, and repackaging under regulated conditions. As a result, Oklo can begin structured isotope recovery and preparation.
The Idaho Radiochemistry Laboratory will serve as the initial processing site for these operations. Furthermore, the facility will manage distribution to authorized recipients under federal rules. This development establishes a controlled pathway toward domestic isotope supply.
Oklo aims to convert disused radioactive materials into usable feedstock for medical isotope production. This approach addresses supply constraints across healthcare and research sectors. It also reduces reliance on foreign isotope sources.
The recovered materials will support applications such as targeted alpha therapy and industrial testing. In addition, the process enhances resource efficiency by reusing materials classified as waste. This strategy aligns with broader nuclear sustainability efforts.
Operational experience from the Idaho laboratory will inform future large-scale facilities. The company plans a multi-reactor isotope foundry with several small reactors. These systems will support diverse uses, including medical, defense, and space technologies.
Oklo also signed an agreement with the U.S. Department of Energy to support its first reactor project. The agreement covers design, construction, and operation under a federal pilot program. This framework accelerates deployment timelines for advanced nuclear systems.
The Department of Energy approved a Nuclear Safety Design Agreement for the Aurora reactor at Idaho National Laboratory. This approval initiates the next stage of technical review and project execution. It also enables further safety analysis under federal oversight.
Oklo continues parallel development of its fuel fabrication facility in Idaho. The facility will produce initial fuel assemblies for the Aurora reactor. Together, these projects strengthen domestic nuclear capacity and support long-term commercial licensing plans.
The post Oklo (OKLO) Stock: Gains 2.35% as NRC License Fuels Isotope Business Expansion appeared first on CoinCentral.
